Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Dec;32(12):1807–1812. doi: 10.1128/aac.32.12.1807

Pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys of (R,S)-9-[4-hydroxy-2-(hydroxymethyl) butyl]guanine, an anti-varicella-zoster virus drug.

D M Lake-Bakaar 1, G Abele 1, B Lindborg 1, K F Soike 1, R Datema 1
PMCID: PMC176023  PMID: 2854453

Abstract

The acyclic guanosine analog (R,S)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine, (+/-)2HM-HBG, is an effective inhibitor of herpes simplex virus and varicella-zoster virus infections in vitro. This report is concerned with the pharmacokinetic evaluation of the drug in rats and monkeys and its antiviral activity in African green monkeys infected with simian varicella virus (SVV), a virus closely related to varicella-zoster virus that is also susceptible to inhibition by (+/-)2HM-HBG. Elimination half-lives in plasma following intravenous administration to monkeys (100 mumol/kg of body weight) ranged from 1.8 to 2.2 h, and total body clearance was 9.0 +/- 0.4 ml/min per kg (mean +/- standard error). After oral administration, levels in plasma were low, with a maximum concentration of the drug of only 3.1 +/- 0.8 microM, a time to reach maximum concentration of drug of 2.7 +/- 0.4 h, and an oral bioavailability of 10.6 +/- 1.4%. Because of the low oral bioavailability, SVV-infected monkeys were treated intramuscularly with (+/-)2HM-HBG. (+/-)2HM-HBG at a dosage of 10 mg/kg of body weight per day allowed moderate viremia, whereas a dosage of 30 mg/kg of body weight per day strongly suppressed viremia with minimal numbers of virus plaques from blood specimens collected at days 3, 5, and 7 postinfection and complete clearance at day 9 postinfection. Titers of antibody to SVV were also low. Treatment three times daily was somewhat more efficacious than treatment twice daily. Thus, (+/-)2HM-HBG is an effective inhibitor of SVV replication in vivo, despite the fact that leves of (+/-)2HM-HBG in plasma were low at extended periods of time and below the concentration of drug giving 50% inhibition of plaque formation obtained in vitro.

Full text

PDF
1807

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abele G., Eriksson B., Harmenberg J., Wahren B. Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate. Antimicrob Agents Chemother. 1988 Aug;32(8):1137–1142. doi: 10.1128/aac.32.8.1137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Abele G., Karlström A., Harmenberg J., Shigeta S., Larsson A., Lindborg B., Wahren B. Inhibiting effect of (RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine on varicella-zoster virus replication in cell culture. Antimicrob Agents Chemother. 1987 Jan;31(1):76–80. doi: 10.1128/aac.31.1.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Datema R., Ericson A. C., Field H. J., Larsson A., Stenberg K. Critical determinants of antiherpes efficacy of buciclovir and related acyclic guanosine analogs. Antiviral Res. 1987 Jul;7(6):303–316. doi: 10.1016/0166-3542(87)90013-1. [DOI] [PubMed] [Google Scholar]
  4. Ericson A. C., Larsson A., Aoki F. Y., Yisak W. A., Johansson N. G., Oberg B., Datema R. Antiherpes effects and pharmacokinetic properties of 9-(4-hydroxybutyl) guanine and the (R) and (S) enantiomers of 9-(3,4-dihydroxybutyl)guanine. Antimicrob Agents Chemother. 1985 May;27(5):753–759. doi: 10.1128/aac.27.5.753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Felsenfeld A. D., Schmidt N. J. Antigenic relationships among several simian varicella-like viruses and varicella-zoster virus. Infect Immun. 1977 Mar;15(3):807–812. doi: 10.1128/iai.15.3.807-812.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Karlsson A. H., Harmenberg J. G., Wahren B. E. Influence of acyclovir and bucyclovir on nucleotide pools in cells infected with herpes simplex virus type 1. Antimicrob Agents Chemother. 1986 May;29(5):821–824. doi: 10.1128/aac.29.5.821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Larsson A., Brännström G., Oberg B. Kinetic analysis in cell culture of the reversal of antiherpes activity of nucleoside analogs by thymidine. Antimicrob Agents Chemother. 1983 Nov;24(5):819–822. doi: 10.1128/aac.24.5.819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Larsson A., Stenberg K., Ericson A. C., Haglund U., Yisak W. A., Johansson N. G., Oberg B., Datema R. Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs related to buciclovir. Antimicrob Agents Chemother. 1986 Oct;30(4):598–605. doi: 10.1128/aac.30.4.598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Roberts E. D., Baskin G. B., Soike K., Gibson S. V. Pathologic changes of experimental simian varicella (Delta herpesvirus) infection in African green monkeys (Cercopithecus aethiops). Am J Vet Res. 1984 Mar;45(3):523–530. [PubMed] [Google Scholar]
  10. Smee D. F., Boehme R., Chernow M., Binko B. P., Matthews T. R. Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and acyclovir in herpes simplex virus-infected and uninfected cells. Biochem Pharmacol. 1985 Apr 1;34(7):1049–1056. doi: 10.1016/0006-2952(85)90608-2. [DOI] [PubMed] [Google Scholar]
  11. Soike K. F., Eppstein D. A., Gloff C. A., Cantrell C., Chou T. C., Gerone P. J. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and recombinant human beta interferon alone and in combination on simian varicella virus infection in monkeys. J Infect Dis. 1987 Oct;156(4):607–614. doi: 10.1093/infdis/156.4.607. [DOI] [PubMed] [Google Scholar]
  12. Soike K. F., Gerone P. J. Acyclovir in the treatment of simian varicella virus infection of the African green monkey. Am J Med. 1982 Jul 20;73(1A):112–117. doi: 10.1016/0002-9343(82)90075-4. [DOI] [PubMed] [Google Scholar]
  13. Stenberg K., Larsson A., Datema R. Metabolism and mode of action of (R)-9-(3,4-dihydroxybutyl)guanine in herpes simplex virus-infected vero cells. J Biol Chem. 1986 Feb 15;261(5):2134–2139. [PubMed] [Google Scholar]
  14. Stenberg K., Wangenheim J., Tribukait B. Quantitative analysis of antiviral drug toxicity in proliferating cells. Cell Biol Toxicol. 1986 Dec;2(4):441–455. doi: 10.1007/BF00117847. [DOI] [PubMed] [Google Scholar]
  15. Sundqvist V. A., Wahren B. Development of sensitive and enzyme-linked immunoassays for herpesvirus antigens and some applications. Dev Biol Stand. 1982;52:245–253. [PubMed] [Google Scholar]
  16. Wahren B., Wahren P., Harmenberg J., Sundqvist V. A. Computer-based virus sensitivity assay and neutralization method. Applications for herpesviruses. J Virol Methods. 1983 May;6(5):271–282. doi: 10.1016/0166-0934(83)90042-3. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES